Corporate Informatiom



Humans have prevailed in the battle with most other species, including bacteria and viruses. The target of medical treatment has changed to systemic diseases that occur without provocation, such as cancers and degenerative diseases.

As an ophthalmologist, when I examine patients with incurable diseases, I always hope to relieve their suffering, but often have a sense of helplessness. One day, Dr. Yoshimura, a professor in the department of ophthalmology at Kyoto University, challenged me to start a bio-venture company. I founded KDDD (Kyoto Drug Discovery & Development Co., Ltd.), which remains affiliated and collaborates with Kyoto University.

KDDD develops KUSs (Kyoto University Substances). The first inventor of a product is Dr. Kakizuka, professor in the graduate school of biostudies at Kyoto University; the second inventor is Dr. Ikeda, associate professor at Kyoto University Hospital. KUSs are novel compounds that improve ATP consumption by inhibiting the ATPase of VCP and protect cells from a lot of kind of damages, such as degeneration and ischemic damage. In animal models, KUSs have neuroprotective effects for chronic degenerative diseases such as retinitis pigmentosa and glaucoma. Our mission is to develop KUSs for treatment of patients with incurable eye disease. As KUSs have a unique mechanism, they may also provide strong cell-protective effects in other diseases.

Our Mission

- strong passion to develop and make drugs available for incurable diseases
- strong social responsibility
- gratitude to society, academia, and the medical field

We promise a sincere commitment to global health.

Our mission is to supply effective drugs for current and future patients with incurable diseases.

代表取締役 武蔵国弘


KDDD aims to bring “Brightness” to patients with incurable diseases, now and in the future, by development of seeds discovered at Kyoto University. KDDD was conceived in the department of ophthalmology and graduate school of biostudies of Kyoto University in May 2015. KDDD, as a university-sponsored venture, will maintain a strong partnership with Kyoto University and promote development of our product.


Corporate name Kyoto Drug Discovery & Development Co., Ltd.
Head Office Eeast Building 2F, #211, International Science Innovation Building, Kyoto University
Labo #416, Med-Pharm Collaboration Building, Kyoto University 46-29 Yoshida-Shimo-Adachi-cho, Sakyo-ku, Kyoto 606-8501 JAPAN
Osaka Office Regus office, 19F Nanba Parks Tower 2-10-70 Nanbanaka Naniwa-ku, Osaka, 556-0011 JAPAN
President & CEO Kunihiro Musashi
Major Business Activities Research and Development of Drug, Diagnostic Drug, Human Cell Therapy and Gene therapy Products, Medical Equipment, Medical Instruments, Reagent and Medical Supplies
Establishment May 15th. 2015
Account Closing Month April
Capital 161.4 mi. yen(as of February 28th, 2018)
Our Bank Bank of Tokyo-Mitsubishi UFJ, Toji Branch Sumitomo Mitsui Banking Corporation, Kyoto Branch


February 28th, 2018

Total 142.8mil. Yen investments from two venture capitals

August 1st, 2017

Labo was established in a building in Kyoto University

September 27th, 2016

Headquarters moves into a building in Kyoto University

June 30th, 2016

Total 430mil. Yen investments from five venture capitals

June 17th, 2016

Capital reached 140mil. Yen (including capital reserve)

March 30th, 2016

License Agreement with Kyoto University

May 15th, 2015

Established (Capital 21mil. Yen)


CEO Kunihiro Musashi
M.D. Ph.D.
COO Sakae Muto
General Manager
Research Promotion Department
Noriyuki Kuno
Director Nobuhiro Yagi
General Manager
CMC Planning Department
Masaki Okamoto
General Manager
Clinical Development Department
Fumiki Hirata
General Manager
Research and Development Department
Nobuaki Miyawaki
CMC Planning Department
Research Promotion Department
Yukiko Yamamoto

about kus

KUSs, Kyoto University Substances, are valosin-containing protein (VCP) modulators. They ameliorated abnormally low ATP levels by inhibiting the ATPase of VCP, thereby protected cells from degeneration and death. Several reports were provided that KUSs have neuroprotective effects that protect retinal nerve fibers and retinal ganglion cells on animal models. The facts may contribute to deterioration restraint of glaucoma. Glaucoma is a leading cause of vision loss worldwide. Lowering intraocular pressure by drugs and/or surgery is the only evidence-based treatment of glaucoma. We believe that KUSs will be able to provide convenient novel therapeutics for neuroprotection in incurable eye diseases such as glaucoma. KUSs may also provide novel strategy for cell protection in other areas.